Aberrations of c-MET drive breast cancer metastasis in an HGF-dominant environment
This study demonstrates that c-MET aberrations drive breast cancer metastasis in a human HGF-dominant environment through a newly identified crosstalk with FGFR3 that activates EMT and immunosuppression, suggesting that combined targeting of MET and FGFR3 is a promising therapeutic strategy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is a disease of great complexity, not a single enemy but a shifting landscape of cells that can behave in wildly different ways. When this disease spreads from its original site to other parts of the body, a process known as metastasis, it becomes far more difficult to treat and is the primary cause of death for patients. For decades, scientists have searched for the specific switches that flip these cells from growing in place to traveling through the bloodstream to colonize distant organs. One such switch involves a protein called c-MET, which sits on the surface of cells like a receiver waiting for a signal. Its partner, a molecule called HGF, acts as the key that fits into this receiver. In healthy bodies, this interaction helps tissues repair themselves, but in cancer, this system can go into overdrive, pushing tumors to grow and spread. However, studying this specific partnership in the lab has been a major hurdle because the standard mouse models used for research do not respond to human versions of these signals, leaving a gap in our understanding of how this mechanism drives the disease in people.
Researchers at The University of Texas MD Anderson Cancer Center set out to fill this gap by building a new kind of experimental model that mimics the human body more closely. They created a special environment where human HGF is present to interact with human c-MET, allowing them to watch exactly what happens when these two components meet in a living system. Their work revealed that when c-MET is either present in excessive amounts or carries a specific genetic glitch, it acts as a powerful engine for metastasis, but only when the surrounding environment is rich with its partner signal, HGF. The study found that a specific mutation in the c-MET gene, known as T1010I, is particularly dangerous, driving cancer to spread more quickly and aggressively than simple overexpression of the normal protein.
To see this in action, the team used a sophisticated mouse model where the animals carried human HGF in their blood, while their breast tumors were engineered to carry either the normal human c-MET or the mutated version. They grew these tumors, removed the primary growth to simulate surgery, and then watched to see if the cancer would return in the lungs, brain, or liver. In mice with the mutated c-MET, the cancer returned in nearly a quarter of the animals, and it did so in just 17 weeks. In mice with the normal, overexpressed c-MET, the cancer spread less frequently and took longer to appear. In the control group, where the tumors had no special c-MET changes, no metastasis occurred at all. This provided direct proof that these specific changes in c-MET are enough to drive the disease to spread, but only when the human HGF signal is present to turn them on.
The researchers then looked inside the cells to understand how this spreading happens. They discovered that the overactive c-MET does not work alone; it triggers a chain reaction that activates another receptor called FGFR3. This unexpected partnership between the two signals pushes the cancer cells to change their shape and behavior, becoming more mobile and invasive, a process scientists call the epithelial-mesenchymal transition. This finding is significant because it suggests that blocking c-MET alone might not be enough to stop the cancer, as the cells could simply switch to using the FGFR3 pathway to survive and spread. The study also observed that these aggressive tumors showed lower levels of a protein called PD-L1, which is often used by cancer cells to hide from the immune system. This observation hints that combining a drug that blocks c-MET with one that targets PD-L1 might be a more effective strategy than using either drug on its own.
Beyond the lab models, the team looked at real human data to see if these patterns held true in patients. They measured the levels of HGF in the blood of women with breast cancer and compared them to healthy women. The results showed that women with breast cancer had significantly higher levels of HGF circulating in their blood. Furthermore, the researchers found a strong link between high levels of HGF and high levels of two other molecules, IL-16 and eotaxin-2, which are known to be involved in helping cancer spread. This correlation suggests that the environment inside a patient's body, specifically the high concentration of these signaling molecules, creates the perfect conditions for c-MET to drive the disease forward.
The study concludes that the relationship between HGF and c-MET is a critical driver of breast cancer metastasis, but it operates within a complex network of other signals. The discovery of the crosstalk with FGFR3 offers a new explanation for why previous treatments targeting c-MET alone have had limited success in clinical trials. By showing that the cancer cells can activate backup pathways, the research points toward a future where doctors might need to block multiple targets simultaneously to effectively stop the spread of the disease. The work also highlights the importance of the specific genetic mutation T1010I, which appears to make the cancer cells even more aggressive by preventing the normal breakdown of the c-MET protein, allowing it to stay active for longer periods. These insights provide a clearer map of the biological terrain, suggesting that future treatments will need to be more comprehensive to outmaneuver the cancer's ability to adapt and survive.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.